Latest / Pharmacy Podcast Network / Certifying the Future: Dr. William Soliman and the Rise of Medical Affairs | PBM Reform
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:09Speaker 1: to the pharmacy profession.
- 0:10Speaker 2: Welcome to the Pharmacy Podcast Network.
- 0:33Speaker 3: Welcome to the PBM Reform Podcast, where we dive deep
- 0:37Speaker 3: into the world of pharmaceutical benefit management, cutting through the
- 0:41Speaker 3: noise to uncover the truth. Since twenty nineteen, we've been
- 0:45Speaker 3: your go to source for the latest on how PBMs
- 0:48Speaker 3: impact patient care, drug pricing, and the very future of pharmacy.
- 0:54Speaker 3: Here we champion the role of pharmacists. The most knowledgeable
- 0:58Speaker 3: advocates for medication safety and expertise. Join us as we
- 1:03Speaker 3: expose and generate discussions that are reshaping healthcare and explore
- 1:07Speaker 3: how we build a better payment system which focuses on
- 1:10Speaker 3: advancing pharmacy care.
- 1:18Speaker 1: Welcome to the PBM Reform Podcast here on the Pharmacy
- 1:22Speaker 1: Podcast Network, my name is Breck Rice. I'll be your
- 1:25Speaker 1: host today and I have the privilege of speaking with
- 1:30Speaker 1: somebody that has done quite a few interviews. In fact,
- 1:34Speaker 1: reason I reached out to doctor Solomon was seeing an
- 1:37Speaker 1: interview he did on TV about about PBMs about drug pricing.
- 1:46Speaker 1: It was really interesting. I thought it was something that
- 1:48Speaker 1: you would all be very interested in hearing about. And
- 1:51Speaker 1: so I want to welcome to the program doctor William Solomon,
- 1:54Speaker 1: PhD and founder and also CEO of a ACMA, and
- 2:03Speaker 1: this is the Credit Accreditation Council for Medical Affairs and
- 2:08Speaker 1: a very interesting background. I would love to get to
- 2:12Speaker 1: know you a little better. But welcome to the show,
- 2:14Speaker 1: doctor Solomon.
- 2:15Speaker 2: Thank you so much, thanks for having me. I appreciate it,
- 2:18Speaker 2: pleasure to be here.
- 2:19Speaker 1: Why don't you tell the audience here just a little
- 2:22Speaker 1: bit more about your background and how you even came
- 2:26Speaker 1: about to saying, hey, there was an opportunity here where
- 2:30Speaker 1: the ACMA needed to be founded.
- 2:33Speaker 2: Yeah. Absolutely, So you know, by background, like you mentioned,
- 2:36Speaker 2: I'm a PhD by training, and we've been working though
- 2:40Speaker 2: in the pharmaceutical industry for almost twenty years. I worked
- 2:44Speaker 2: in the pharmaceutical industry kind of did everything you get
- 2:47Speaker 2: imagined in the industry, from being a pharmaceutical sales rep
- 2:49Speaker 2: when I started out my early twenties and then eventually
- 2:54Speaker 2: becoming a medical science liaison heading up MSL teams and
- 2:58Speaker 2: medical affairs organizeds. So I've done a lot of different things.
- 3:02Speaker 2: Work for big form a, mid sized biotechs, rare disease,
- 3:05Speaker 2: you know, other more traditional areas and working for all
- 3:10Speaker 2: these different companies over the years, what I uncovered is
- 3:13Speaker 2: that a lot of the companies when it comes to
- 3:17Speaker 2: establishing standards and benchmarks for excellence in terms of practice
- 3:22Speaker 2: and competencies for the pharmaceutical industry, sales reps, the medical
- 3:27Speaker 2: science liaisons or even now the Filder reimbursement professionals, there
- 3:31Speaker 2: wasn't any There was nothing. So until the ACMA was
- 3:34Speaker 2: founded almost now and now it's been over ten years,
- 3:37Speaker 2: there were no standards or a benchmark of excellence for
- 3:42Speaker 2: these professions. There was nothing in the industry. So we
- 3:47Speaker 2: were the first back in twenty fifteen to establish a
- 3:52Speaker 2: benchmark of excellence and standards for the medical science liaison profession,
- 3:57Speaker 2: the medical affairs profession, pharma sales. And today you know,
- 4:02Speaker 2: we're the leaders in the space. Our certifications and our
- 4:06Speaker 2: standards have become the go to for all pharmaceutical companies.
- 4:09Speaker 2: We work today with over three hundred pharmaceutical companies and
- 4:14Speaker 2: we've been invited by the US Congress. So in twenty
- 4:17Speaker 2: twenty one, I went before the US Congress Health Subcommittee
- 4:21Speaker 2: and did a briefing. At the time, Congressman Brett Guthrie
- 4:26Speaker 2: out of the great state of Kentucky talking about the
- 4:28Speaker 2: importance of standards. So it's really been great to see
- 4:32Speaker 2: the evolution in terms of what we do. And I think,
- 4:35Speaker 2: you know, there's a lot of scrutiny in the pharmaceutical
- 4:37Speaker 2: industry because of the nature of the industry and the
- 4:40Speaker 2: fact that a lot of people wonder about things like
- 4:43Speaker 2: drug pricing, like we were just mentioning I talked about
- 4:46Speaker 2: the other day on television. I talk about it a
- 4:47Speaker 2: lot with the Trump tariff issue. Wire drug price is
- 4:51Speaker 2: so high. You know, what are PBMs, what's their role?
- 4:53Speaker 2: And you know when Trump talks about them as a midileman,
- 4:56Speaker 2: what does that mean. So I think we've been able
- 4:59Speaker 2: to do with the ACMA is bring a lot of
- 5:00Speaker 2: these important issues to light, because in the end of
- 5:04Speaker 2: the day, if these things are obstacles for patients being
- 5:09Speaker 2: able to access medications, it becomes an issue. So I
- 5:12Speaker 2: think having a benchmark for the profession elevates the profession
- 5:16Speaker 2: in the industry, but also holds them accountable. So that's
- 5:19Speaker 2: what we're here to do.
- 5:20Speaker 1: Yeah, that's excellent, And so tell us a little bit
- 5:24Speaker 1: about where your background. Where did you get your PhD from?
- 5:28Speaker 2: Sure. So my PhD. My background's in biochemistry by molecular chemistry.
- 5:33Speaker 2: I got it from Columbia University in New York and
- 5:38Speaker 2: went undergrad to New York University NYU the Bachelor's of Biochemistry.
- 5:43Speaker 2: And you know, raised, born and raised in the New
- 5:48Speaker 2: Jersey area. Some I'm a New York, New Jersey guy.
- 5:51Speaker 2: And our offices today are in the local New York,
- 5:56Speaker 2: New Jersey area, in the Premise, New Jersey area for
- 5:58Speaker 2: those that are familiar with the New York Tristate area.
- 6:01Speaker 2: So we're really you know, I like to say we're
- 6:03Speaker 2: a local company in the New York, New Jersey area,
- 6:05Speaker 2: but we have a global footprint. We actually have learners
- 6:09Speaker 2: in gosh now over probably over one hundred countries, which
- 6:12Speaker 2: is crazy that when I say that, we have learners
- 6:15Speaker 2: that are enrolled in our programs from everywhere you can imagine,
- 6:19Speaker 2: from Europe to South America. We have people in azer
- 6:23Speaker 2: by John and Turkey and Lebanon and all these countries.
- 6:27Speaker 2: It's pretty amazing because you know, the pharmacutical industry, of
- 6:32Speaker 2: course is global. You know, there's there's professionals over the world.
- 6:37Speaker 1: Yeah. Absolutely, well, Columbia not a not a an easy
- 6:44Speaker 1: school to get into. You must have done well in
- 6:46Speaker 1: your undergrad Yeah.
- 6:48Speaker 2: Well, you know, I was school you know, luckily, knock
- 6:51Speaker 2: on Wood always came easily to me. So I was
- 6:54Speaker 2: always pretty, you know, pretty good student. You know. Colombia
- 6:59Speaker 2: is Yeah, it's a challenging school to get into, but
- 7:04Speaker 2: it was great. It was a great experience for me.
- 7:06Speaker 2: It was a very very you know, rigorous academic experience,
- 7:12Speaker 2: which I think is good. It kind of gives you,
- 7:15Speaker 2: you know, the ability to really make sure that you
- 7:17Speaker 2: can apply strong work ethic. So I think you learn
- 7:20Speaker 2: a lot of good work ethic at places like Columbia NYU. Yeah.
- 7:24Speaker 1: Yeah, about twenty four years ago, I believe it was
- 7:29Speaker 1: I got the opportunity to visit the campus. I was
- 7:33Speaker 1: invited to come back and speak to their School of Journalism.
- 7:37Speaker 2: Oh nice.
- 7:38Speaker 1: Yeah, it was got a tour of the campus and
- 7:41Speaker 1: meet some of the students that were in that program,
- 7:45Speaker 1: the journalism program at that time. But yeah, that's been many,
- 7:49Speaker 1: many years ago. But yeah, what a wonderful campus. And
- 7:54Speaker 1: sounds like you had a good experience there too as well.
- 7:57Speaker 1: So well, let's find out a little bit more what
- 8:03Speaker 1: you had discussed on the on the interview that I
- 8:06Speaker 1: was mentioning earlier because you were talking about you know,
- 8:11Speaker 1: HEBMS and and also just wanted to understand their claim
- 8:17Speaker 1: to helping lower costs, that that's the PBM's claim, but
- 8:23Speaker 1: what's the actual reality and why is you know, why
- 8:28Speaker 1: is Trump saying, hey, there needs to be some adjustments here.
- 8:31Speaker 1: It wasn't It wasn't to affect the patient other than
- 8:36Speaker 1: lowering the prices. But understood that there was somebody in
- 8:38Speaker 1: the middle that was kind of controlling that.
- 8:41Speaker 2: Exactly what a lot of people don't realize is in
- 8:45Speaker 2: the pharmaceutical industry, when we set up price, that list price,
- 8:50Speaker 2: that's not really what the former company collects because there's
- 8:53Speaker 2: many steps in the process. And for the pharmaceutical industry, unfortunately,
- 8:58Speaker 2: there's an intermediary which we call the pharmacy benefit manager
- 9:01Speaker 2: or the PBM, that provides. What they're claiming is they
- 9:07Speaker 2: provide a way to able to lower the price for
- 9:10Speaker 2: the patient by negotiating discounts and rebates and things like that.
- 9:16Speaker 2: But the issue is that the way that the pharmacy
- 9:19Speaker 2: benefit manager makes money is by getting a rebate back
- 9:25Speaker 2: basically from the pharmaceutical company, and they get a percentage
- 9:29Speaker 2: of that. So the higher the cost of the drug,
- 9:34Speaker 2: the greater their rebate. Actually, and I think a lot
- 9:38Speaker 2: of people realize that, so it almost forces a pharma
- 9:44Speaker 2: company to have to increase the price to make up
- 9:46Speaker 2: for that. Right. So, if there wasn't a PBM and
- 9:50Speaker 2: the pharma company could just go directly to the payer
- 9:54Speaker 2: or the insurance company, that would make things a lot easier.
- 9:57Speaker 2: But what happens is there's this you know, organanization or
- 10:01Speaker 2: these PBMs that then not just negotiate the discounts and
- 10:05Speaker 2: the rebates and whatnot, but then they control where the
- 10:10Speaker 2: drug goes in the formulary. And that is another problem
- 10:14Speaker 2: because now formulary think of it as you know, different
- 10:18Speaker 2: tiers or classes. You know, think about like you know,
- 10:22Speaker 2: if you're in an airplane, you have first class, business class,
- 10:25Speaker 2: you know, economy plus and coach. I use that analogy,
- 10:28Speaker 2: I think for people that maybe aren't in the industry
- 10:30Speaker 2: or aren't familiar, because what I found is people even
- 10:34Speaker 2: in the industry, even healthcare providers, they are not how
- 10:36Speaker 2: it works. And to be honest, I don't blame them
- 10:38Speaker 2: because it's very complex. But if you think about that
- 10:42Speaker 2: in a plane, right, you have all these different classes.
- 10:46Speaker 2: Everybody wants to be first class. Right, it's expensive to
- 10:49Speaker 2: be first class. It's kind of the same way with
- 10:50Speaker 2: a drug. You want to be in the top tier.
- 10:54Speaker 2: Why do you want to be if you're a drug
- 10:55Speaker 2: in the top tier Because if you're in the top tier,
- 10:59Speaker 2: then you get a lower co pay as a patient
- 11:03Speaker 2: to get that drug. So if the drugs in the
- 11:05Speaker 2: top tier, it lowers the co pay for the patient,
- 11:10Speaker 2: so the patient has a lower burden have to get
- 11:12Speaker 2: the drug, they have to pay less. Right, So all
- 11:17Speaker 2: the all the pharma companies they're bidding, they're trying to
- 11:19Speaker 2: be top tier. But to become top tier sometimes a
- 11:24Speaker 2: lot of shenanigans happens. And that's where I think Trump
- 11:28Speaker 2: is saying, we need to re examine this. And by
- 11:30Speaker 2: the way, Trump, in his first administration, to his credit,
- 11:35Speaker 2: in my opinion, he brought this up. He brought this
- 11:38Speaker 2: issue up of the middlemen or the PBMs. But then
- 11:42Speaker 2: COVID happened. And when COVID happened, it obviously sidetracked everything
- 11:46Speaker 2: and people, you know, weren't paying attention to that. But
- 11:49Speaker 2: this is an issue that was brought up in his
- 11:52Speaker 2: first administration, even the tariffs. By the way, this was
- 11:55Speaker 2: something that he brought up in his first administration. But
- 11:57Speaker 2: again I think with COVID, a lot of things that
- 12:00Speaker 2: he had wanted to accomplish he wasn't able to accomplish.
- 12:03Speaker 2: So I think, you know, from my perspective, although I
- 12:05Speaker 2: know Trump gets a lot of criticism, I think what
- 12:09Speaker 2: he's trying to do, whether it's with the tariffs or
- 12:13Speaker 2: the PBMs, I think ultimately is going to be a
- 12:16Speaker 2: positive for the United States, for the American public, because one,
- 12:21Speaker 2: we have a lot of reliance on foreign countries for
- 12:26Speaker 2: our medications. You know, I talked about this the other day,
- 12:29Speaker 2: you know, when I was on News Nation Elizabeth Vargas.
- 12:31Speaker 2: I was talking to her about the concern because if
- 12:35Speaker 2: you are relying heavily on countries like China and India,
- 12:38Speaker 2: which by the way, I don't know if you know,
- 12:40Speaker 2: a lot of times the FDA can get into audit
- 12:43Speaker 2: they're factories, they're they're manufacturing facilities, so we don't really
- 12:47Speaker 2: know what the quality is. Like There's been a few
- 12:49Speaker 2: hundred deaths due to low quality products being produced for
- 12:54Speaker 2: you know, counterfeit products. People get sick in the best
- 12:59Speaker 2: case scenario. Sometimes you see situations where the product is
- 13:03Speaker 2: not efficacious. We've seen a lot of series like this
- 13:06Speaker 2: in Africa and South Africa in particular, they import a
- 13:08Speaker 2: lot of drugs from China. They've had a lot of
- 13:10Speaker 2: problems with that. So going back to the issue of
- 13:14Speaker 2: standards that we were talking about at the outset, the
- 13:17Speaker 2: truth is that we as a country need to make
- 13:22Speaker 2: sure we have better control on these types of things.
- 13:24Speaker 2: So I think forcing farm and manufacturers to invest domestically
- 13:29Speaker 2: is important. And by the way, one of the things
- 13:31Speaker 2: that people don't know about the ACMA, Like I mentioned
- 13:34Speaker 2: about word at over eighty countries, we have an office
- 13:36Speaker 2: in for example, Saudi Arabia. Why I bring up Saudi
- 13:39Speaker 2: Arabia is Saudi Arabia today they're trying to mobilize their
- 13:44Speaker 2: workforce and what they're saying is we want to focus
- 13:47Speaker 2: on our population and helping them grow their talent. We
- 13:51Speaker 2: want to invest domestically in our country. So why I
- 13:54Speaker 2: bring that up is that a lot of countries do that.
- 13:57Speaker 2: So I don't know why there's a lot of criticism,
- 14:00Speaker 2: you know, when it comes to Trump on wanting to
- 14:03Speaker 2: push pharmer companies to invest and we saw a few
- 14:06Speaker 2: weeks ago many of the big pharma roche nevardes Eli
- 14:10Speaker 2: Lilly said that we're going to now invest in building
- 14:13Speaker 2: manufacturing plans. That's a good thing for the for the country.
- 14:16Speaker 2: That's a positive him. Yeah.
- 14:18Speaker 1: Yeah. Unfortunately, it doesn't matter who the president president is,
- 14:24Speaker 1: they're going to always be you know, criticized for everything
- 14:28Speaker 1: that's done by at least you know, forty percent to
- 14:31Speaker 1: fifty percent of the population. Unfortunately, it just does seem
- 14:35Speaker 1: like that President Trump does get a little more of
- 14:39Speaker 1: the share than most presidents though, unfortunately. So yeah, let's
- 14:44Speaker 1: let's go back doctor William to the formulary to maybe
- 14:50Speaker 1: help understand. Does anyone else control what goes on the formularity?
- 14:55Speaker 1: Is that completely decided by a PBM?
- 15:00Speaker 2: Well, the insurers do, the payers do? Because remember the
- 15:03Speaker 2: payers they want to minimize what they pay out. Like
- 15:07Speaker 2: any other insurance company, they want to minimize what they
- 15:10Speaker 2: have to pay. You know, we all know that people
- 15:14Speaker 2: with you know, home insurance, car insurance, something breaks in
- 15:16Speaker 2: your house or something happens, the insurance, you know, they
- 15:20Speaker 2: don't want to pay right. It's no different when it
- 15:23Speaker 2: comes to health insurance providers and what happens a lot
- 15:25Speaker 2: of times. Is they set in place a lot of
- 15:31Speaker 2: barriers that make it difficult to get reimbursement a lot
- 15:35Speaker 2: of times. And probably the biggest way they do this
- 15:38Speaker 2: is through prior authorization. Now, I don't know if you
- 15:41Speaker 2: know this, the ACMA, we actually have the first and
- 15:45Speaker 2: only it's become the standard now for the country Prior
- 15:49Speaker 2: Authorization Certified Specialist Program. It's a certification program for prior
- 15:53Speaker 2: authorization professionals. A lot of the filer reimbursement professionals enroll
- 15:56Speaker 2: in it. It's the number one program in the country
- 15:58Speaker 2: for this. And what we found and working in the
- 16:02Speaker 2: space is that the number one reason for care delay,
- 16:08Speaker 2: the number one reason for care delay in America is
- 16:12Speaker 2: due to prior authorization. Three percent of care delay is
- 16:16Speaker 2: due to prior authorizations and they cost people, you know,
- 16:20Speaker 2: in the healthcare space billions of dollars a year. So
- 16:25Speaker 2: why I bring this up is that the control happens,
- 16:29Speaker 2: you know, on both ends. The control happens and you're
- 16:31Speaker 2: making it difficult for the healthcare provider to write particular
- 16:34Speaker 2: prescriptions or it could be a medical benefit, you know,
- 16:38Speaker 2: particular service or diagnostic and then the other on the
- 16:41Speaker 2: other side, making it difficult for the drug to be
- 16:45Speaker 2: in a preferred formulary status in terms of being placed
- 16:48Speaker 2: in those preferred tiers. And there's one last thing that
- 16:51Speaker 2: I would say impacts and that people aren't aware of,
- 16:55Speaker 2: that's related to demand. Part of the game is that
- 17:02Speaker 2: the pharmaceutical company needs to create demand. If there's high
- 17:06Speaker 2: demand for the product, that can push it to go
- 17:11Speaker 2: up to a more preferred formulary status or preferred tier
- 17:14Speaker 2: in the formulary because there's demand, so that that makes
- 17:19Speaker 2: a big difference as well. The one last thing I'll
- 17:22Speaker 2: say is that a lot of the drugs today that
- 17:26Speaker 2: are coming through the pipeline, most of which are you know,
- 17:29Speaker 2: oncology drugs or cancer drugs, but there's a lot of
- 17:32Speaker 2: rare disease or ultra rare disease orphan products. Why I
- 17:36Speaker 2: bring this up is that about two three weeks ago
- 17:38Speaker 2: in the news, something came out that again a lot
- 17:41Speaker 2: of people may not have noticed, but that's important, which
- 17:45Speaker 2: is that the FDA's new Commissioner, Marty McCarey, is trying
- 17:49Speaker 2: to push for more accelerated or facilitated approval for rare
- 17:55Speaker 2: disease products based on what the mechanism of action. That's
- 18:00Speaker 2: a big deal. Remember historically in America, to get a
- 18:04Speaker 2: drug to market, you need to have randomized controlled clinical trials.
- 18:11Speaker 2: But what they're saying is that for rare disease products,
- 18:14Speaker 2: it's difficult a lot of times to get a sample
- 18:18Speaker 2: size that's big enough to power the trial adequately to
- 18:23Speaker 2: be able to get approval at the standards the administration
- 18:26Speaker 2: is looking for, the FD is looking for. So what
- 18:29Speaker 2: he's proposed is, let's try to get this facilitated approval
- 18:33Speaker 2: just based on whether whether or not the mechanism of
- 18:36Speaker 2: action is plausible. So you can imagine a world where
- 18:39Speaker 2: you would have these rare disease products based really on
- 18:42Speaker 2: surrogate endpoints. Why I bring that up is that what
- 18:45Speaker 2: you may see is that a lot of prescriptions are
- 18:48Speaker 2: going to be written for these products off label. So
- 18:51Speaker 2: I'm curious to see, if they're written off label, how
- 18:55Speaker 2: that will impact reimbursement, because remember, if something's written on label,
- 19:01Speaker 2: the insurance company may give pushback in terms of reimbursement.
- 19:04Speaker 2: And for those that are listening, what I mean by
- 19:06Speaker 2: all label here is that it's written for an indication
- 19:10Speaker 2: not in the package insert not in the label that
- 19:13Speaker 2: was approved by the FDA. So for example, if you know,
- 19:16Speaker 2: I'll use an example, people know about well, Golovi for obesity.
- 19:19Speaker 2: Right if someone says, you know, what a doctor says,
- 19:22Speaker 2: you know, I think will Goovi helps with headaches and
- 19:24Speaker 2: they write a prescription for Gobi for headaches, that would
- 19:26Speaker 2: be an off label indication.
- 19:28Speaker 1: Rights most of our pain medications started as a cancer
- 19:34Speaker 1: treatment first before they off label were used.
- 19:38Speaker 2: Exactly.
- 19:38Speaker 1: It also helps with migraines or you know whatever, exactly.
- 19:44Speaker 1: Very interesting. So when when you think about this this
- 19:49Speaker 1: whole you know bill that that everyone's talking about, and
- 19:55Speaker 1: wondering what the trickle down effects are going to be,
- 19:58Speaker 1: specifically to community farm because I see the intention, right
- 20:02Speaker 1: that Trump is trying to is to cut out some
- 20:07Speaker 1: of the spread pricing that PBMs are you taking advantage
- 20:12Speaker 1: of today? And we know they make billions of dollars
- 20:17Speaker 1: and they have shareholders that they have to report to,
- 20:20Speaker 1: and so they need to continue to make those billions
- 20:23Speaker 1: of dollars. So what's that trickle down effect? Because I
- 20:26Speaker 1: see the intention is there to do good by the patient,
- 20:31Speaker 1: But what is that trickle down going to be either
- 20:34Speaker 1: to you know, lowering the costs for the patient. But
- 20:37Speaker 1: then what is the pharmacy, the community pharmacy going to
- 20:40Speaker 1: end up getting, you know, messed up over this as well.
- 20:47Speaker 2: I think for the community pharmacies stay a lot of
- 20:50Speaker 2: these independent pharmacies, which by the way, I've founded US
- 20:54Speaker 2: Pharmacy Allowed one of my other businesses years ago, over
- 20:57Speaker 2: ten years ago. That was one of my first companies.
- 21:00Speaker 2: I found that we were an independent pharmacy, had a
- 21:02Speaker 2: compounding lab as well that I'm now sold. But so
- 21:06Speaker 2: I have a lot of familiarity with this area that
- 21:08Speaker 2: the issue really that they face is that a lot
- 21:14Speaker 2: of times what the insurance reimburses them is the same
- 21:20Speaker 2: or less than what they actually need to be able
- 21:23Speaker 2: to make a profit. And I don't know, I don't
- 21:27Speaker 2: know if this is going to change that much unfortunately.
- 21:30Speaker 2: I know that's bad news for pharmacists listening out there
- 21:32Speaker 2: in a community pharmacy, But I don't know if it's
- 21:35Speaker 2: going to make much of a difference to the pharmacy
- 21:38Speaker 2: right for because a lot of times, and you see
- 21:41Speaker 2: this a lot of times, the pharmacists would say, look,
- 21:45Speaker 2: if you pay out a pocket, you can actually pay less.
- 21:50Speaker 2: Right we saw that sometimes happening with pharmacists. So I
- 21:53Speaker 2: don't know for pharmacists though, if this will have much
- 21:56Speaker 2: of an impact to them at that level. I think
- 21:59Speaker 2: the bigger challenge that's a whole other topic, But the
- 22:01Speaker 2: bigger challenge for community pharmacies that I saw is dealing
- 22:06Speaker 2: with these big changes, right because like CBS has their
- 22:09Speaker 2: own PBM, and that that makes it difficult. How do
- 22:13Speaker 2: you deal with that? Right? Because they're buying in bulk,
- 22:16Speaker 2: their costs they're buying, you know, so per item their
- 22:20Speaker 2: cost is less, they can charge less. It's hard to
- 22:23Speaker 2: deal with that at the community level. I think what
- 22:25Speaker 2: community pharmacies have and I think will always have is service.
- 22:30Speaker 2: I still use a community pharmacy. I use a local
- 22:32Speaker 2: independent pharmacy because I feel then, I feel I see
- 22:36Speaker 2: that they have much better service. So I think that's
- 22:39Speaker 2: an area where they can excel. But I don't think
- 22:42Speaker 2: this particular particular issue will have much of an impact
- 22:45Speaker 2: for them.
- 22:46Speaker 1: Yeah, well, doctor William, do you want to give a
- 22:48Speaker 1: shout out to that independent pharmacy.
- 22:51Speaker 2: I do. It's called US Pharmacy Labs. So it's the
- 22:54Speaker 2: one pharmacy that I owned that's local here in the area.
- 22:58Speaker 2: David Yun who is the owner of the pharmacy there.
- 23:02Speaker 2: He's phenomenal. He's fantastic, very responsive and delivers our medications
- 23:06Speaker 2: when we need it within an hour. You know, he'll
- 23:08Speaker 2: have the team deliver it. So, you know, having a
- 23:11Speaker 2: good pharmacist, having a really great community pharmacist that understands
- 23:16Speaker 2: the patients at that level of depth in terms of
- 23:19Speaker 2: the relationship, that's huge and I think we've missed that
- 23:22Speaker 2: in America with these big chains.
- 23:24Speaker 1: Yeah, and it's really unfortunate because if you look at
- 23:27Speaker 1: the actual staff, pharmacists themselves had a big chain. They
- 23:32Speaker 1: they want to give that service, but they're you know,
- 23:35Speaker 1: they're kind of have those golden handcuffs that say these
- 23:38Speaker 1: are the three things that you need to do, and
- 23:42Speaker 1: you can't come out from behind the bench and walk
- 23:46Speaker 1: down an aisle with the patient and explain the differences
- 23:49Speaker 1: between you know, this cold medicine versus that cold medicine,
- 23:53Speaker 1: which you know, obviously you get that level of customer
- 23:57Speaker 1: service when you go to an independent Yeah. I absolutely
- 23:59Speaker 1: love independent pharmacies and they you know, the service that
- 24:05Speaker 1: they provide and give and then also how quick they
- 24:08Speaker 1: are too. Right, you may wait several hours to get
- 24:12Speaker 1: a prescription, you know at a chain, when you can
- 24:15Speaker 1: get it in ten minutes or less at any you know,
- 24:18Speaker 1: community independent community pharmacy.
- 24:20Speaker 2: So I tell you a true story in the town
- 24:24Speaker 2: when we owned, when we owned the pharmacy, we had
- 24:27Speaker 2: a woman whose daughter had had an asthma attack, okay,
- 24:33Speaker 2: and she had a prescription you know, in the pharmacy,
- 24:36Speaker 2: but the mom, I don't know what happened, she couldn't
- 24:38Speaker 2: get it anyway. That morning, the mom called frantically and said,
- 24:43Speaker 2: you know, my daughter was having an asthma attack. She
- 24:45Speaker 2: she was playing outside and she can't breathe. She's about
- 24:47Speaker 2: to pass out. And the pharmacist went over. They drove
- 24:52Speaker 2: over with the inhaler to the house, administered the inhaler
- 24:58Speaker 2: to the to the to the girl and then she
- 25:00Speaker 2: was okay. But that story always stuck with me because
- 25:05Speaker 2: that's the kind of like level of care as hell,
- 25:09Speaker 2: because you know, pharmaciy are health care providers that I
- 25:12Speaker 2: think we missed. Today. We don't have that relationship with
- 25:14Speaker 2: our pharmacists anymore, you know what I mean.
- 25:17Speaker 1: Yeah, that's amazing story, absolutely amazing. So you know, back
- 25:21Speaker 1: to you know, policies and and you know, different things
- 25:28Speaker 1: that that the the you know that the pharmacy benefit
- 25:32Speaker 1: managers put in place where they say they're helping, you know,
- 25:37Speaker 1: either control costs or make sure it's the right medication
- 25:41Speaker 1: on the formulay. In your opinion, what's the most frustrating
- 25:46Speaker 1: or damaging PBIUM tactic or policy that that currently exists today.
- 25:52Speaker 2: I think there's two things. One I think is price
- 25:55Speaker 2: gouging when they're trying to force the companies to give
- 25:59Speaker 2: them a bigger rebate, which forces the cost to go
- 26:02Speaker 2: up on the list price. I think the second thing
- 26:04Speaker 2: is ambiguity in the policies. Ambiguity, you know, if people
- 26:11Speaker 2: don't realize is if you and I we both go
- 26:14Speaker 2: get let's say an MRI, and we get the NMRI
- 26:18Speaker 2: for the exact same thing, what you're going to get
- 26:22Speaker 2: charged for your MRI or what I'm going to get
- 26:24Speaker 2: charged can be very very different. And why we don't know,
- 26:29Speaker 2: we don't know, we don't know why, we don't know
- 26:31Speaker 2: how that gets negotiated. No one's really clear about that,
- 26:35Speaker 2: and there's nothing legally to force them to be transparent
- 26:40Speaker 2: about those contracts. So I think, to me, the lack
- 26:44Speaker 2: of transparency is a big problem.
- 26:48Speaker 1: Yeah, yeah, absolutely, you know, when we're looking at that
- 26:52Speaker 1: trickle down effect, which you know all community pharmacy is
- 26:56Speaker 1: concerned about right now, you know, what's what's the new
- 27:00Speaker 1: drug pricing going to mean for them? And are they
- 27:03Speaker 1: still going to be able to cover their overhead. One
- 27:06Speaker 1: of the other trickle down effects that I don't think
- 27:10Speaker 1: that was really explored until it already happened was with
- 27:16Speaker 1: the Department of Labor. So DL went out for bid
- 27:20Speaker 1: for new contract and to look at, you know, should
- 27:24Speaker 1: they change their current pharmacy benefit manager. And the incumbent
- 27:28Speaker 1: won the request for proposal, but another big PBM wanted
- 27:35Speaker 1: that book of business and so they sued to put
- 27:38Speaker 1: a stay in place to make the federal government have
- 27:41Speaker 1: to reopen the bid again. That went. That process happened
- 27:44Speaker 1: two or three times until the big PBM just came
- 27:48Speaker 1: in and undercut and said, okay, we'll do it for
- 27:52Speaker 1: you know, these prices on these top medications, not realizing
- 27:57Speaker 1: what the trickle down effect was going to be. Now today,
- 28:01Speaker 1: an independent pharmacy can't afford to fill the script for
- 28:06Speaker 1: a postal worker or any federal employee because the rate
- 28:10Speaker 1: is just so low that it doesn't even cover the
- 28:14Speaker 1: cost of the medication, let alone their overhead.
- 28:17Speaker 2: Yeah, I'm not surprised. I'm not surprised to hear that.
- 28:19Speaker 2: And you know, that's terrible, especially for for that group
- 28:23Speaker 2: of people right who you know, they're they're they're middle
- 28:26Speaker 2: class and and they're struggling to begin with a lot
- 28:29Speaker 2: of them. If the if you're older and you have
- 28:31Speaker 2: cool morbid conditions, now you're on multiple medications, what do
- 28:34Speaker 2: you do in that situation? So that's that's terrible. That's why,
- 28:37Speaker 2: that's why I think we have to do something about it.
- 28:39Speaker 2: That's why going back to what the current White House
- 28:42Speaker 2: administration is doing, I support it. I think long term
- 28:45Speaker 2: it makes sense.
- 28:47Speaker 1: Yeah, also really frustrating to see, you know, community pharmacies
- 28:50Speaker 1: trying to survive but being forced into networks that they
- 28:55Speaker 1: don't need. And so you've got a lot of bundling
- 28:58Speaker 1: out there with the big uh, you know, controlling PBMs.
- 29:02Speaker 1: So there's the three major PBMs that everybody knows and
- 29:05Speaker 1: they control about eighty percent of the lives, and but
- 29:10Speaker 1: they've they've gotten really wise to bundle networks or they
- 29:15Speaker 1: buy other PBMs and then bundle that PBM into into
- 29:19Speaker 1: their network. And and so it's really hard for a
- 29:22Speaker 1: community pharmacy to say, okay, we we we want to
- 29:26Speaker 1: be in network with all of your commercial payers, your
- 29:30Speaker 1: healthcare patients. But this network for you know, auto injury
- 29:35Speaker 1: just doesn't add up for us, or this network for
- 29:38Speaker 1: workers comp just doesn't work for us. Plus most of
- 29:42Speaker 1: them would have another option, but now the big PBMs
- 29:47Speaker 1: force them and say, hey, if you want you know,
- 29:49Speaker 1: these sixty five million lives over here, you're going to
- 29:52Speaker 1: It's all or nothing. You're either in network or out
- 29:54Speaker 1: of network. And so that really takes the opportunity for
- 29:59Speaker 1: an independent community pharmacy to make the better reimbursements they
- 30:03Speaker 1: could have going with another partner or another PBM in fact,
- 30:09Speaker 1: but they're stuck with going with one of the big
- 30:12Speaker 1: three that they know that they're going to, you know,
- 30:15Speaker 1: make pennies versus what they could on going with a
- 30:19Speaker 1: you know, another provider.
- 30:20Speaker 2: And can I tell you from my experience, I remember
- 30:24Speaker 2: trying to apply to be in network with these different PBMs.
- 30:29Speaker 2: It's a nightmare. It is a nightmare. They make it
- 30:34Speaker 2: so difficult. It's just terrible. The process is terrible. And
- 30:39Speaker 2: I'm convinced that they do it on purpose to make
- 30:42Speaker 2: it difficult, and it takes by the way, it takes months,
- 30:47Speaker 2: it could take months to get in. I'm sure you've
- 30:49Speaker 2: heard horror stories about it, but it's terrible, terrible experience.
- 30:54Speaker 2: So that that's the whole other thing. I think that's
- 30:56Speaker 2: another tactic potentially, because they really want to discourage new
- 31:00Speaker 2: independent pharmacies from coming up. They don't want them, yep,
- 31:04Speaker 2: you know, they try to buy them or.
- 31:05Speaker 1: Yeah, yeah, or a new transparent, fully transparent PBM to
- 31:11Speaker 1: try to break into the market. No, they really, you know,
- 31:14Speaker 1: they don't want transparency, so they want to make it
- 31:18Speaker 1: as convoluted as possible so that they can add in
- 31:21Speaker 1: their additional margins that they're they're going to make the
- 31:25Speaker 1: spread up pricing. And yeah, so I think, you know,
- 31:30Speaker 1: unbundling those networks and allowing through transparency for a pharmacy
- 31:35Speaker 1: to choose what network makes sense for them and which
- 31:38Speaker 1: ones don't make sense, I think would be a huge
- 31:41Speaker 1: help as well. Do you think patients even understand how
- 31:45Speaker 1: much the middleman, you know, has control over the cost
- 31:50Speaker 1: of their medication or is that another one of those
- 31:52Speaker 1: that it's kind of behind the scenes, and patients don't
- 31:55Speaker 1: even really understand that.
- 31:58Speaker 2: I would say unforced and most don't, you know, most
- 32:01Speaker 2: don't understand how these things work. I think when you
- 32:06Speaker 2: work in the healthcare space, you take a lot for
- 32:09Speaker 2: granted that you know, right, So for me, for example,
- 32:13Speaker 2: I've been working in this space for a very long time,
- 32:17Speaker 2: and a lot of my friends and colleagues who don't
- 32:20Speaker 2: work in this area, when I tell them some of
- 32:22Speaker 2: this stuff, they're shocked, they're shocked. They can't believe it.
- 32:27Speaker 2: So they don't know. They don't understand why things are
- 32:31Speaker 2: the way they are in terms of how things get
- 32:34Speaker 2: priced out and things like that. So no, I think
- 32:38Speaker 2: that's another area, probably from an educational perspective, like patient education.
- 32:45Speaker 2: It's so important. For maybe that's the government's role to
- 32:49Speaker 2: educate patients. You know, if you listen, if you ask
- 32:52Speaker 2: most people what's the difference between Medicare and Medicaid, the
- 32:57Speaker 2: average person, they don't know. They don't. You don't. That's again,
- 33:04Speaker 2: that's been my experience. You know, if I ask somebody
- 33:07Speaker 2: that question and it's just they just don't know. It's again,
- 33:12Speaker 2: it's a complex system. The healthcare system is complex. How
- 33:16Speaker 2: you know, in every other area in industry, you buy something,
- 33:21Speaker 2: you pay a price and you get it received, and
- 33:24Speaker 2: that's sad. You get whatever the item is that you
- 33:26Speaker 2: that you paid for received, and healthcare is very different,
- 33:29Speaker 2: you know, it's a very different process. And so how
- 33:35Speaker 2: things are calculated in terms of what you're going to
- 33:39Speaker 2: pay out of pocket, what the hospital charges or the
- 33:42Speaker 2: doctor charges, it's a mystery and it's funny. I tell
- 33:48Speaker 2: you a quick story. One of my friends who I
- 33:51Speaker 2: met here in the town where I live, he used
- 33:54Speaker 2: to live in the uee in Dubai and when he
- 34:00Speaker 2: first came over here, he had tennis elbow. Okay, he
- 34:05Speaker 2: got he had gotten injured and he got tennis elbow.
- 34:07Speaker 2: So he went to do physical therapy and he thought that,
- 34:13Speaker 2: you know, for example, for each physical therapy session, they
- 34:17Speaker 2: were going to charge the insurance company, let's say two
- 34:19Speaker 2: hundred dollars per session, for example, and that's it. The
- 34:23Speaker 2: the then they pay the insurance company that he because
- 34:25Speaker 2: he's paying for the insurance to his employer, they paid,
- 34:29Speaker 2: he pays the insurance company, they pay the physical therapist
- 34:32Speaker 2: to insure the insure and uh, and that's it, you know,
- 34:36Speaker 2: and then he was surprised to get a bill, a
- 34:39Speaker 2: big bill on top of what he's paying for the insurance.
- 34:43Speaker 2: And he came to me because he knows what I
- 34:46Speaker 2: what I do, and he's like, I don't become confused.
- 34:50Speaker 2: I'm paying, you know, two three thousand dollars a month
- 34:53Speaker 2: for insurance, you know, through my my insurance, my company.
- 34:57Speaker 2: And he pays a portion of that, so he might
- 34:58Speaker 2: pay a few hundred bucks a month, but still the company,
- 35:00Speaker 2: between him and the company, they're paying a lot of
- 35:02Speaker 2: money for the payer. He's like, so, why if they're
- 35:05Speaker 2: paying the physical therapist, why do I have to pay
- 35:08Speaker 2: on top of that all this other money? Like way,
- 35:10Speaker 2: where did that come from? And so I explained to him,
- 35:15Speaker 2: and I got to tell you. He was shocked. He said, wow,
- 35:17Speaker 2: and Dubui, whatever service you get, you get an antibiotic,
- 35:23Speaker 2: you get physical therapy, whatever it is, you never pay
- 35:26Speaker 2: more than I think he told me, like ten bucks
- 35:27Speaker 2: or twelve bucks. It was something like that, and he
- 35:30Speaker 2: just he couldn't understand. And I joke about it till
- 35:35Speaker 2: now with him. He's been here for a few years.
- 35:37Speaker 2: Because that story always stuck with me because you know,
- 35:40Speaker 2: if you're coming from another country and you now experience
- 35:45Speaker 2: the US healthcare system. It doesn't make sense when you
- 35:48Speaker 2: think about it. It's not logical.
- 35:51Speaker 1: Yeah. No, I was speaking to a group of CEOs
- 35:55Speaker 1: for self insured companies out here in Phoenix, and we
- 35:59Speaker 1: were discussing workers' compensation benefits. And it's such an afterthought
- 36:07Speaker 1: because you know, number one, they don't ever plan for
- 36:10Speaker 1: anyone ever getting hurt. But the reality is somebody is
- 36:13Speaker 1: going to get hurt. But to understand and and follow
- 36:17Speaker 1: the money of what they're paying for it with that injury,
- 36:22Speaker 1: they were not not one CEO in that room fully
- 36:27Speaker 1: understood it. They had bits and pieces, but they didn't
- 36:30Speaker 1: know that they were paying for you know, bill review
- 36:33Speaker 1: to make sure that they paid the right amount for
- 36:36Speaker 1: the for the prescription medication. They didn't know that the
- 36:39Speaker 1: difference between the pricinges and the different tiers that you
- 36:42Speaker 1: talked about earlier, you know, with the medication formularies. It
- 36:47Speaker 1: was It was pretty, i guess, eye opening to me
- 36:51Speaker 1: that here were these you know, industry leaders that also
- 36:55Speaker 1: didn't understand how complex they And that was just one segment.
- 36:59Speaker 1: We were just focusing just on workers compensation and the
- 37:03Speaker 1: and the medical spin not the medical sorry that the
- 37:06Speaker 1: pharmacy spinned under that we didn't even get into the
- 37:08Speaker 1: medical side, which is a whole other can of worms.
- 37:11Speaker 2: Right. Yeah, So I.
- 37:14Speaker 1: Know when you when you owned your your pharmacy, your
- 37:17Speaker 1: compounding pharmacy, was there an experience that that you had
- 37:22Speaker 1: that you remember where you know a that that was
- 37:26Speaker 1: damaging to one of your patients because of a hebim
- 37:31Speaker 1: either decision or or formulary or if you were making
- 37:36Speaker 1: custom medications. Can you remember and call an experience?
- 37:40Speaker 2: Yeah, so a lot of times was and I know
- 37:42Speaker 2: there's a lot of controversy with compounding.
- 37:45Speaker 1: It was.
- 37:46Speaker 2: It's a tough it's a tough business, especially after what
- 37:49Speaker 2: happened in New England with the whole meningita situation. You
- 37:52Speaker 2: probably remember years ago. But but what I can tell
- 37:56Speaker 2: you is many patients, especially patients unfortunately you had cancer.
- 38:01Speaker 2: This was terrible. Many of that had cancer, the delay
- 38:05Speaker 2: in them getting their treatment because of these issues, these
- 38:09Speaker 2: administrative burdens like prior authorization. That was terrible. Many stories
- 38:15Speaker 2: where the people couldn't get treatment because they had to
- 38:19Speaker 2: wait a few weeks and they needed the treatment. That
- 38:22Speaker 2: was tough to see. And you know, we saw obviously,
- 38:26Speaker 2: what is it now, six seven months ago, what happened
- 38:30Speaker 2: to the United Healthcare CEO who got murdered by Luigi Mangioni,
- 38:34Speaker 2: which of course there's no justification with that. It's terrible situation,
- 38:37Speaker 2: and you know, that's crazy what happened. And my heart
- 38:42Speaker 2: goes out to the United Healthcare CEO's family. But my
- 38:45Speaker 2: point is that think about the level of anger that
- 38:51Speaker 2: this guy must have had to go out and murder
- 38:54Speaker 2: this United Healthcare ceo, and then look at the reaction
- 39:00Speaker 2: of the public. Of course, you know, I mean, look,
- 39:05Speaker 2: nothing justifies murdering somebody. I mean, that's that's that's that's
- 39:10Speaker 2: that's that's clearly evident. However, the fact that you had
- 39:16Speaker 2: a lot of people on social media cheering this guy
- 39:20Speaker 2: on the murderer as if he was a hero, that's scary. Yeah,
- 39:25Speaker 2: that's really scary. But I also think it points to
- 39:28Speaker 2: something important that Americans are frustrated. They're frustrated by the
- 39:33Speaker 2: system today. They're frustrated by the fact that they can't
- 39:37Speaker 2: get their medications when they need to. They're frustrated by
- 39:40Speaker 2: the increase of cost, They're frustrated by the lack of
- 39:44Speaker 2: transparency and and and especially people in lower socioeconomic conditions.
- 39:49Speaker 2: There's a lot of data on this. I'm sure you know,
- 39:52Speaker 2: people with lower socio economic status typically fair worse when
- 39:56Speaker 2: it comes to healthcare outcomes. We know that, you know,
- 40:00Speaker 2: so there needs to be something done about that. And
- 40:03Speaker 2: I think again, thinking about ways to educate patients, thinking
- 40:08Speaker 2: about ways to streamline prior authorization. I'll tell you, when
- 40:12Speaker 2: we train a lot of the people who are doing
- 40:14Speaker 2: the prior authorizations, many of them tell us we never
- 40:19Speaker 2: got training on how to do it. We don't even
- 40:21Speaker 2: know how to approach this problem. So which is why
- 40:24Speaker 2: I think that the PAX program is called what we
- 40:25Speaker 2: call the PAX program, the prior authorization served by Special
- 40:27Speaker 2: Program White so popular is because it's the only structured
- 40:31Speaker 2: program really in the country that's accredited and gives you
- 40:35Speaker 2: that training for field reimbursement or prior authorization. But we
- 40:39Speaker 2: need it because the healthcare providers, staff members, they're kind
- 40:43Speaker 2: of handicapped in the sense they don't have the knowledge,
- 40:45Speaker 2: they don't have the training to deal with all these
- 40:47Speaker 2: pushbacks from the payers. So you know, I would say that,
- 40:54Speaker 2: if anything, I think that the Luigi Mangioni, murderer of
- 40:59Speaker 2: the of the un Healthcare CEOs with the watershed moment,
- 41:03Speaker 2: so watershed moment, it reminds me of the opioid crisis.
- 41:06Speaker 2: And you might say, how's that related the opioid crisis back,
- 41:10Speaker 2: I guess now it's sixty seven years ago when it
- 41:14Speaker 2: really kind of blew up when Purdue Pharma, Jane j
- 41:17Speaker 2: when they all were, you know, getting sued by the
- 41:20Speaker 2: different states and whatnot. That was a watershed moment because
- 41:24Speaker 2: that told us that without proper standards for pharma companies,
- 41:31Speaker 2: people go rogue. Sometimes not all the time. Look, most
- 41:34Speaker 2: of the people are in the pharmacutical industry, they're excellent, but
- 41:38Speaker 2: you have some people that you know, operate unethically, and
- 41:42Speaker 2: that's why you need something that level sets increates uniformity
- 41:46Speaker 2: or in terms of competencies. And I think the same
- 41:48Speaker 2: holds true with the with the prioritization situation. I think
- 41:51Speaker 2: health insurance, you know, kind of went became prime time
- 41:55Speaker 2: when this issue happened, as murder happened, because people are like, well, wait, what,
- 41:59Speaker 2: you know, why why murder the United Healthcare CEO? What
- 42:02Speaker 2: does the United Healthcare do? What is a pair. What's
- 42:05Speaker 2: their role in is what is prior authorization going to
- 42:07Speaker 2: mind a black who don't know?
- 42:09Speaker 1: Well know, Yeah, you bring up a good point with
- 42:12Speaker 1: the states taking action, right, and we've recently seen several
- 42:17Speaker 1: states start to take action against HEBM owned pharmacies, right,
- 42:24Speaker 1: so Arkansas probably being the one of the leaders in that,
- 42:29Speaker 1: but there's thirty some odd other state district attorneys that
- 42:33Speaker 1: have jumped on that bandwagon and said, hey, this is
- 42:35Speaker 1: a pretty good idea, maybe we shouldn't have HEBM owned
- 42:39Speaker 1: pharmacies in our state. What do you think is going
- 42:42Speaker 1: to come of that?
- 42:45Speaker 2: I think it could potentially cause a domino effect across
- 42:49Speaker 2: the country because there's a conflict of interest I was
- 42:53Speaker 2: talking about earlier with these big chain pharmacies that they
- 42:57Speaker 2: have their own PBM. To me, that's a conflict of interest,
- 43:01Speaker 2: and I'm surprised until now that nothing's been done about it.
- 43:04Speaker 2: But you know, again, they have powerful lobbying groups and
- 43:09Speaker 2: it's difficult sometimes to elicit change given that. But I
- 43:13Speaker 2: think we need to see that across the country if
- 43:15Speaker 2: we're going to really expect any type of appreciable change. Yeah.
- 43:20Speaker 1: Yeah, to your point that there's not only powerful lobbying groups,
- 43:26Speaker 1: but also many many attorneys on staff too. That these
- 43:31Speaker 1: big PBMs and big chains have certainly going to be
- 43:37Speaker 1: some pushback. I would I would guess on the state's
- 43:40Speaker 1: decision to say, hey, we no longer wanted anybum owned
- 43:46Speaker 1: pharmacy in our state.
- 43:48Speaker 2: Yeah. Oh, I'm sure. I mean, it's just like the pushback. Look,
- 43:53Speaker 2: there was pushback at what was it a few weeks
- 43:55Speaker 2: ago when when Trump announced the whole thing about making
- 43:59Speaker 2: sure that we had pricing for our drugs that was
- 44:03Speaker 2: comparable to other countries. Remember that that executive order that
- 44:07Speaker 2: he passed, and right away, you know, insurance of pharma
- 44:11Speaker 2: companies their attorneys began to mount a legal battle against
- 44:15Speaker 2: the executive order. So I'm sure that's going to happen.
- 44:19Speaker 1: Yeah. Are there any other changes in reform that you
- 44:24Speaker 1: would like to see happen?
- 44:29Speaker 2: You know? I think one of the things against is
- 44:31Speaker 2: a kind of a tangential topic is related to biosimilars
- 44:36Speaker 2: in biologics. I think for people that don't know bio
- 44:40Speaker 2: biosimilars or generic versions of a biologic, you know, And
- 44:45Speaker 2: I think it would be important as more and more
- 44:48Speaker 2: biosimilars come to market. That we better understand or have
- 44:55Speaker 2: better standards and practices around reimbursement policies there, because that
- 45:00Speaker 2: kind of a new area in many ways, biosimilars and biologics,
- 45:04Speaker 2: and I think having more clarity there is going to
- 45:06Speaker 2: be important because look, ultimately, biosimilars, they present a very
- 45:10Speaker 2: good opportunity to get these expensive drugs at a cheap cost,
- 45:16Speaker 2: right at a much less expensive cost. So figuring that
- 45:20Speaker 2: out and how to reimburse for that is going to
- 45:22Speaker 2: be important.
- 45:23Speaker 1: I think that is past past due in having that
- 45:29Speaker 1: coming around, right. Oh yeah, one hundred Percentfully that'll happen.
- 45:32Speaker 3: So well.
- 45:34Speaker 1: I want to thank you so much for being our
- 45:37Speaker 1: guest today and just for our listening audience. Want to
- 45:41Speaker 1: do a rapid fire fun facts about you. This is
- 45:45Speaker 1: just super fun. First thing that comes into your head,
- 45:48Speaker 1: really easy. So are you more of an early bird or.
- 45:51Speaker 2: A night out early bird?
- 45:54Speaker 1: Okay? And do you prefer the mountains or the beach,
- 45:57Speaker 1: the beach, coffee, tea or something else.
- 46:03Speaker 2: I'm actually mostly a water drinker, good for you, not
- 46:08Speaker 2: really coffee or tea.
- 46:10Speaker 1: Yeah that's excellent, excellent, Well, thank you so much, doctor
- 46:13Speaker 1: William Solomon for being our guest today. I'm CEO and
- 46:18Speaker 1: founder of acm A and it's been a pleasure of
- 46:22Speaker 1: getting to know you better and having you on the podcast.
- 46:25Speaker 1: You're listening to the PBM Reform podcast here on the
- 46:28Speaker 1: Pharmacy Podcast Network. My name is Brett Rice and always
- 46:34Speaker 1: advocate for community pharmacies. They really are the heart of
- 46:38Speaker 1: our community. And thank you so much for being here
- 46:42Speaker 1: and being our guest today, doctor William. It's great to
- 46:45Speaker 1: get to know you.
- 46:46Speaker 2: Yeah, real pleasure. Thank you so much.
- 46:49Speaker 1: All Right, until next time, Stay curious everyone,